1. National Institute for Health and Care Excellence. Age-related macular degeneration. 2018. Available at: https://www.nice.org.uk/guidance/ng82/ [Accessed April 30, 2020].
2. European Medicines Agency. Lucentis. 2018. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis [Accessed November 8, 2020].
3. National Institute for Health and Care Excellence (NICE). Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008.
4. Center for drug evaluation and research. BLA application number: 125156. Approval Letter. 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_Lucentis_APPROV.pdf.
5. Center for drug evaluation and research. BLA application: 125387Orig1s000. Approval Letter. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000Approv.pdf.